BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

Healthcare Biotechnology

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by frankmanon Dec 20, 2024 12:24pm

46 Views

Post# 36372391

1.7 mil shares traded (1/2 day) / $US OTC BVAXF 800k~ .065

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr
ATS	43.0	0.06	·	0.065	404.5	0.065	+0.005	8.3	848.4	50	52
CSE - C	43.0	0.06	·	0.065	404.5	0.065	+0.005	8.3	463.0	27	24
NEO ATS - U						0.06			2.0	0	1
Omega - O						0.06			226.0	14	14
CX2 - H						0.06			131.0	8	9
CXD - D						0.06			0.5		1
TriAct - M						0.06			25.9	1	3